Serving Japanese sponsors from Singapore: what a regional central lab must get right before the first shipment
Summary
- A Japanese sponsor sends samples to Singapore mostly when a test is not available at home and the clock is short: in one lab network's own case, a flow cytometry panel with a stability period of 48 hours was run in Singapore on samples shipped from Japan as an interim solution. 1
- In Japan the sponsor chooses the lab, the final say sits with the R&D general manager, and data quality, site satisfaction and project management outweigh price. 2 3
- Wet service decides: finished kits, flexible pick-up, fast answers in Japanese, a Japanese-language help desk and weekend collection; sponsors also want import and export bundled into the budget. 4 5 6
- Singapore is a short regulatory door for trials, with a standard Clinical Trial Authorisation turnaround of 30 working days and 5 working days for a Clinical Trial Notification, but a vendor's count of 1,179 trials for 2020 to 2025 is only an order of magnitude. 7 8
- Competitors are already here: one global network's Singapore central lab dates from 2000 and spans more than 6,300 m2, so an address is not an advantage. 9
- Japanese sponsors accept a premium only for long-term storage, kit production and scientific consultation, and want fixed-price packages; the risk is that interim work moves home when the Japan lab gets the panel. 10 11 1
Transcript
01Why samples come to Singapore at all
You run operations at a central lab in Singapore. When does a Japanese sponsor actually send you samples?
Mostly when the test they need is not available at home and the clock is short. The cleanest public example I know comes from a competitor's own case study, so read it as their account. A leading Japanese drug maker planned a regional trial of 3 to 4 years built around a flow cytometry immunology panel. The samples were stable for only 48 hours, and the trial sites were not even decided when the lab was chosen. The network's Japan lab did not have the panel, its Singapore central lab did, so the samples were picked up in Japan and shipped to Singapore as an interim solution until the technology was transferred to the Japan lab. 1
The word that matters there is interim. The technology was moved to the Japan lab afterwards, so a Singapore lab in a Japanese programme can be a bridge, and I plan my capacity on that basis. 1 The other pull is money. Sponsors in Japan told KIRA's analysts that because Japan is expensive, some testing may move to Singapore and other Asian markets so that the same budget buys more tests. 12
How big is Singapore as a trial location? Is the volume there?
I only trust what I can check. A vendor's blog from this March says Singapore hosted 1,179 clinical trials between 2020 and 2025. I cannot verify that against a registry, so I treat it as an order of magnitude, not a market size. 8 What I can point to is the regulatory door. The Health Sciences Authority's standard turnaround for a Clinical Trial Authorisation is 30 working days, and a Clinical Trial Notification takes 5 working days. For a sponsor planning a regional study I think that matters more than the headline count. 7
02Who decides, and on what
In Japan, who chooses the central lab? The CRO or the sponsor?
From what Japanese sponsors told KIRA's analysts, the sponsor chooses, not the CRO. The final decision sits with the R&D general manager and purchasing has little say. 2 So a Singapore lab's pitch has to reach the R&D head, and it has to talk about the study, not a price list. 2
And what do they weigh when they choose?
Data quality, satisfaction of the investigator sites and project-management experience outweigh price in those interviews. Cost matters, but it is judged against quality. 3 Relationships are also sticky: sponsors keep to a small set of labs for their Asian and global studies, and the ties last for years. 13
So how does a newcomer get onto that short list at all?
Through a study the sponsor cannot do at home, as in the case I described. 1 After that, through the sites and the project manager, who tell the R&D head whether you were easy to work with. 3 Origin matters less than people think. Japanese sponsors say a lab's nationality does not count by itself, but fluency in Japanese and Japanese business practice do for domestic work. For a regional study run from Singapore I would not assume the language bar is lower, only that it is different. 14
03What wet service means in practice
Japanese sponsors talk about wet service. What do they mean?
It is the opposite of what they call dry. Sponsors expect complete, pre-assembled kits, flexible pick-up times and quick answers in Japanese, and they see foreign labs as dry and tied to the contract. 4 The complaints are very concrete. A foreign lab sent a bundle of loose tubes where a Japanese lab would have sent a finished kit with the sample. There was no help desk in Japanese and every query had to be written in English. 5
A third complaint is weekend collection. With no weekend pick-up, a Friday draw ends up arriving on Sunday. 5 If I were setting up a Singapore lab for Japanese work I would start with exactly those three: kits built complete, a pick-up calendar that follows the site's week, and a Japanese-speaking project contact. None of them is high technology. 4
Does the paperwork matter as much as the service?
More than outsiders expect. Purchasing staff prefer Japanese contracts and find local providers faster with documents. 15 That is a real hurdle for a Singapore lab, so I would prepare a Japanese-language contract and document set early. Japanese providers are moving the other way at the same time: they know they are weak in studies outside Japan, they are hiring language-capable staff and learning import and export procedures, and they follow their sponsors abroad with Japanese-language interfaces. So you are not racing an empty field. 16
04Getting samples and supplies across the border
What worries sponsors most on the logistics side?
Import and export of samples. Sponsors find it troublesome, they want it bundled into the total budget, and some will not use a lab without that experience. 6 That is why I tell newcomers the freight and the paperwork are not a side service. They are part of the product. 6
What does the Singapore rulebook say about it?
I will be careful here. The public guidance I know best is from Singapore Customs, and it is about trial materials, not patient samples. Goods explicitly classed as clinical trial materials, meaning medicinal products, Class 2 cell, tissue and gene therapy products, therapeutic products and their placebos, can come in with GST relief for regulated trials here or for destruction after overseas trials, and the cell, tissue and gene therapy, therapeutic and placebo categories can also come in for export to overseas trials. You need Health Sciences Authority import approval or notification, a claimant account, and a TradeNet permit with the place of receipt code CTM and item descriptions starting with CTM. For specimens I check with the regulators shipment by shipment, and I would not give you a rule from memory. 17
And on the supply side, who handles drugs and kits for trials here?
Singapore has depth there. One clinical supply site says on its website that it is certified by the Health Sciences Authority for GMP and GDP and covers import and export, cold-chain management, storage and distribution and returns. It cites over 25 years of trial supply chain expertise, a licence to import and re-export investigational medicinal products, and importer-of-record services for Australia, Taiwan, South Korea and others. That is the company's own statement. 18 But it tells me the neighbours for a sponsor's regional programme are already here, and I would rather partner than rebuild what they have. 18
05Competition, and why Japan's rules matter
Who are you up against in Singapore?
The global networks are already here. One of them says its Singapore central laboratory started in 2000, spans more than 6,300 m2 within combined facilities of over 7,300 m2, and offers safety testing, flow cytometry, genomics, immunology, microbiology and specimen management. That is their own description. 9 So a new regional lab does not win by having a Singapore address. To a Japanese sponsor, service and project management carry more weight than price. 3
Does Japanese regulation change how much work leaves Japan?
It can. PMDA's 2023 notification says additional phase 1 trials in Japanese subjects are not required when safety and tolerability in Japanese participants can be adequately explained from existing data and safety is clinically acceptable and manageable. It also expects developers to consider Japanese participants in multiregional trials early in development. I read that as more Japanese patients in regional studies and so more samples crossing borders, though I cannot tell you how fast. The same article says PMDA opened an Asia Office in Bangkok in July 2024, which tells me it is watching the region. 19
Japanese sponsors also told KIRA's analysts that regulatory acceptance of North Asian data increases the number of regional studies involving Korea, China and Taiwan. 20 That is the direction I would build for. 20
06Price and packaging
How should a Singapore lab price for Japanese sponsors?
As a comprehensive fixed-price package. Sponsors' willingness to pay for add-on services is very low. They want one budget that includes kits, transport and the import and export work. 10 A premium is accepted only for long-term specimen storage, kit production and scientific consultation, and only a small one. So I would price kit and logistics inside the base package and keep the premium list short. 11
Is the cheapest lab at a disadvantage then?
07Advice to a newcomer, and what worries me
A new regional lab, perhaps backed by a Japanese or Korean group, wants to serve Japanese sponsors from Singapore. Where should it start?
With one study type the sponsor cannot do at home, done the way a Japanese lab would do it: finished kits, a Japanese-speaking contact and a pick-up calendar that follows the site. 4 Put the logistics in the contract and the budget. 6 And invest in people. Japanese providers told KIRA's analysts that staff quality is their main constraint and that they run their own training centres. I would expect the same to be true here. 21
What would change your mind about this opportunity, and what worries you?
What worries me is that word interim. If a sponsor's Japan lab brings the panel home, the Singapore work ends, and a lab built only on that bridge has nothing under it. 1 My second worry is that the headline numbers are thin: the trial count I quoted comes from a vendor blog I could not check. 8
What would change my mind is a sponsor telling me it will run its Asian programmes from Singapore as the base, not the bridge. Sponsors keep to a small set of labs for a long time, so I would believe it when a contract moves, not when somebody says so. 13
Sources and basis
- 1Labcorp case study dated 28 March 2024 (the company's own account): a leading Japanese pharmaceutical company needed a flow cytometry immunology panel for a regional trial planned for 3 to 4 years; trial samples had a short stability period of 48 hours and the trial sites were not yet decided; Labcorp's Japan lab lacked the panel while its Singapore central lab had it; Labcorp picked up and shipped samples from Japan to Singapore as an interim solution until the technology was transferred to its local Japan labPublic source · Labcorp case study on sample logistics and its central lab network, 28 Mar 2024 · link
- 2In Japanese pharmaceutical companies the sponsor, not the CRO, chooses the central lab; the final decision sits with the R&D general manager and purchasing has little sayKIRA field interviews · KIRA field interviews, Japanese pharmaceutical sponsors and laboratory providers
- 3Data quality, investigator-site satisfaction and project-management experience outweigh price; cost matters but is judged against qualityKIRA field interviews · KIRA field interviews, Japanese pharmaceutical sponsors and laboratory providers
- 4Japanese sponsors expect wet service: complete pre-assembled kits, flexible pick-up times and fast answers in Japanese; foreign labs are seen as dry and contract-boundKIRA field interviews · KIRA field interviews, Japanese pharmaceutical sponsors and laboratory providers
- 5Sponsors' complaints about foreign labs: a bundle of loose tubes where a Japanese lab would send a finished kit with the sample; no help desk in Japanese so every query has to be in English; no weekend sample collection, so a Friday draw arrives on SundayKIRA field interviews · KIRA field interviews, Japanese pharmaceutical sponsors and laboratory providers
- 6Import and export of samples is seen as troublesome; sponsors want it bundled into the total budget, and some will not use a lab without that experienceKIRA field interviews · KIRA field interviews, Japanese pharmaceutical sponsors and laboratory providers
- 7Health Sciences Authority turnaround times for clinical trial applications: Clinical Trial Authorisation (CTA) 30 working days; 15 working days for Phase 1 trials that solely evaluate bioequivalence, bioavailability, food effect or drug-drug interactions; 60 working days for Class 2 cell, tissue and gene therapy product trials; Clinical Trial Notification (CTN) 5 working days; counted in working days and excluding stop-clock time for clarification requestsPublic source · Health Sciences Authority, CTA/CTN application page, last updated 8 Sep 2026 · link
- 8A vendor blog states that between 2020 and 2025 Singapore hosted 1,179 clinical trials (a secondary, promotional source; the figure was not checked against a registry)Public source · Lifebit blog, 3 Mar 2026 (vendor blog, secondary) · link
- 9Labcorp says its Singapore central laboratory started in 2000 and spans more than 6,300 m2, within combined laboratory facilities of over 7,300 m2; the assay menu includes safety testing, flow cytometry, anatomic pathology and histology, special chemistry, targeted cell isolation, genomics, immunology, microbiology and specimen management (the company's own statement)Public source · Labcorp Drug Development website, Singapore page, viewed Oct 2026 · link
- 10Willingness to pay for add-on services is very low; sponsors want comprehensive fixed-price packagesKIRA field interviews · KIRA field interviews, Japanese pharmaceutical sponsors and laboratory providers
- 11A premium is accepted only for long-term specimen storage, kit production and scientific consultation, and only a small oneKIRA field interviews · KIRA field interviews, Japanese pharmaceutical sponsors and laboratory providers
- 12Rising trial costs in Japan push sample generation and testing into other Asian markets, since the same budget then runs more testsKIRA field interviews · KIRA field interviews, Japanese pharmaceutical sponsors and laboratory providers
- 13Sponsors keep to a small set of labs for Asian and global studies and a few local labs for domestic studies; the relationships are long and stickyKIRA field interviews · KIRA field interviews, Japanese pharmaceutical sponsors and laboratory providers
- 14The origin of the lab, Japanese or foreign, does not matter by itself; for domestic work, fluency in Japanese and Japanese business practice doKIRA field interviews · KIRA field interviews, Japanese pharmaceutical sponsors and laboratory providers
- 15Purchasing staff prefer Japanese contracts and find local providers faster with documentsKIRA field interviews · KIRA field interviews, Japanese pharmaceutical sponsors and laboratory providers
- 16Domestic labs know they are weak in studies outside Japan and are hiring language-capable staff and learning import/export procedures; domestic providers expand regionally by following Japanese sponsors and offering Japanese-language interfaces abroadKIRA field interviews · KIRA field interviews, Japanese laboratory providers
- 17Singapore Customs guidance: goods explicitly classed as clinical trial materials (medicinal products, Class 2 cell, tissue and gene therapy products, therapeutic products and their placebos) can be imported with GST relief for regulated trials in Singapore or for destruction after overseas trials, and Class 2 cell, tissue and gene therapy products, therapeutic products and placebos can also be imported for export to overseas trials; this requires Health Sciences Authority import approval or notification, a Claimant Account with Singapore Customs, and a TradeNet permit with place of receipt code CTM and item descriptions prefixed CTM; non-CTM goods must go under a separate In-Payment (GST) permit. The page concerns trial medicines and therapeutic products, not patient specimensPublic source · Singapore Customs, importing medicinal products and therapeutic products for clinical trials, page last updated 23 Feb 2026 · link
- 18Catalent's Singapore site is 31,000 sq. ft., certified by the Health Sciences Authority for GMP and GDP, and offers import/export, cold-chain management, storage and distribution, and returns; it is licensed to import and re-export investigational medicinal products and clinical ancillaries; the page cites over 25 years of clinical trial supply chain expertise and importer-of-record services for Australia, Taiwan, South Korea and others (the company's own statement)Public source · Catalent Singapore website, viewed Oct 2026 · link
- 19DIA Global Forum article (September 2025 issue): PMDA's 2023 regulatory notification says additional phase 1 trials in Japanese subjects are not required when safety and tolerability in Japanese participants can be adequately explained from existing data and safety is clinically acceptable and manageable; PMDA expects developers to consider including Japanese participants in multiregional trials early in development; PMDA opened an Asia Office in Bangkok in July 2024Public source · DIA Global Forum, Around the Globe: Japan, September 2025 issue · link
- 20Regulatory acceptance of North Asian data increases regional studies involving Korea, China and TaiwanKIRA field interviews · KIRA field interviews, Japanese pharmaceutical sponsors and laboratory providers
- 21Staff quality is the main constraint as demand rises; providers run their own training centresKIRA field interviews · KIRA field interviews, Japanese laboratory providers